ArticleThe Journal of clinical endocrinology and metabolism2016
Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of clinical endocrinology and metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis.American journal of preventive medicine · 2022 · on this mapPooled it
- Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2020 · on this mapPooled it
- Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study.Diabetes care · 2021Trial
- Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle.Scientific reports · 2021Trial
- Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.Diabetes care · 2016Trial
- Berberine Alleviates Pancreatic β-Cell Ferroptosis and Injury in db/db Mice by Regulating the AGE/RAGE Pathway: Insight from Proteomic Analysis.Current medical science · 2026Article
- Pathobiology of Prediabetes: Understanding and Interrupting Progressive Dysglycemia and Associated Complications.Diabetes · 2025Review
- Obesity in Prediabetic Patients: Management of Metabolic Complications and Strategies for Prevention of Overt Diabetes.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Nonlifestyle Treatment of Prediabetes.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Metformin plus lifestyle interventions versus lifestyle interventions alone for the delay or prevention of type 2 diabetes in individuals with prediabetes: a meta-analysis of randomized controlled trials.Diabetology & metabolic syndrome · 2024Review
- Exploring Folklore Ecuadorian Medicinal Plants and Their Bioactive Components Focusing on Antidiabetic Potential: An Overview.Plants (Basel, Switzerland) · 2024Review
- Should Prediabetes be Treated Pharmacologically?Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Amelioration of diabetes and its complications byJournal of diabetes and metabolic disorders · 2022Article
- Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?Molecular metabolism · 2021Review
- Prediabetes and What It Means: The Epidemiological Evidence.Annual review of public health · 2021Review
- Influence of Cinnamon on Glycemic Control in Individuals With Prediabetes: A Randomized Controlled Trial.Journal of the Endocrine Society · 2020Article
- Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure.Nature reviews. Endocrinology · 2020Review
- Regression from prediabetes to normal glucose regulation: State of the science.Experimental biology and medicine (Maywood, N.J.) · 2020Review
- Article
- Roles of Perilipins in Diseases and Cancers.Current genomics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 1 country.
Devjit TripathyTexas Diabetes Institute and University of Texas Health Science Center (D.T., N.M., R.A.D.), South Texas Veterans Health Care System, San Antonio, Texas 78229; Phoenix VA Health Care System (D.C.S., P.D.R.), Phoenix, Arizona 85012; College of Nursing & Health Innovation (D.C.S.), Arizona State University, Phoenix, Arizona 85281; SUNY Health Science Center at Brooklyn (M.A.B.), Brooklyn, New York 11203; Pennington Biomedical Research Center (G.A.B.), Louisiana State University, Baton Rouge, Louisiana 70803; University of Southern California Keck School of Medicine (T.A.B.), Los Angeles, California; Inova Fairfax Hospital (S.C.C.), Falls Church, Virginia 22042; VA San Diego Healthcare System and University of California, San Diego (R.R.H., S.M.), San Diego, California 92093; Division of Endocrinology, Diabetes and Metabolism (A.E.K., F.B.S.), University of Tennessee-Memphis, Memphis, Tennessee; and Medstar Research Institute (R.E.R.), Hyattsville, Maryland 20782.
Dawn C SchwenkeTexas Diabetes Institute and University of Texas Health Science Center (D.T., N.M., R.A.D.), South Texas Veterans Health Care System, San Antonio, Texas 78229; Phoenix VA Health Care System (D.C.S., P.D.R.), Phoenix, Arizona 85012; College of Nursing & Health Innovation (D.C.S.), Arizona State University, Phoenix, Arizona 85281; SUNY Health Science Center at Brooklyn (M.A.B.), Brooklyn, New York 11203; Pennington Biomedical Research Center (G.A.B.), Louisiana State University, Baton Rouge, Louisiana 70803; University of Southern California Keck School of Medicine (T.A.B.), Los Angeles, California; Inova Fairfax Hospital (S.C.C.), Falls Church, Virginia 22042; VA San Diego Healthcare System and University of California, San Diego (R.R.H., S.M.), San Diego, California 92093; Division of Endocrinology, Diabetes and Metabolism (A.E.K., F.B.S.), University of Tennessee-Memphis, Memphis, Tennessee; and Medstar Research Institute (R.E.R.), Hyattsville, Maryland 20782.
MaryAnn BanerjiTexas Diabetes Institute and University of Texas Health Science Center (D.T., N.M., R.A.D.), South Texas Veterans Health Care System, San Antonio, Texas 78229; Phoenix VA Health Care System (D.C.S., P.D.R.), Phoenix, Arizona 85012; College of Nursing & Health Innovation (D.C.S.), Arizona State University, Phoenix, Arizona 85281; SUNY Health Science Center at Brooklyn (M.A.B.), Brooklyn, New York 11203; Pennington Biomedical Research Center (G.A.B.), Louisiana State University, Baton Rouge, Louisiana 70803; University of Southern California Keck School of Medicine (T.A.B.), Los Angeles, California; Inova Fairfax Hospital (S.C.C.), Falls Church, Virginia 22042; VA San Diego Healthcare System and University of California, San Diego (R.R.H., S.M.), San Diego, California 92093; Division of Endocrinology, Diabetes and Metabolism (A.E.K., F.B.S.), University of Tennessee-Memphis, Memphis, Tennessee; and Medstar Research Institute (R.E.R.), Hyattsville, Maryland 20782.
George A BrayTexas Diabetes Institute and University of Texas Health Science Center (D.T., N.M., R.A.D.), South Texas Veterans Health Care System, San Antonio, Texas 78229; Phoenix VA Health Care System (D.C.S., P.D.R.), Phoenix, Arizona 85012; College of Nursing & Health Innovation (D.C.S.), Arizona State University, Phoenix, Arizona 85281; SUNY Health Science Center at Brooklyn (M.A.B.), Brooklyn, New York 11203; Pennington Biomedical Research Center (G.A.B.), Louisiana State University, Baton Rouge, Louisiana 70803; University of Southern California Keck School of Medicine (T.A.B.), Los Angeles, California; Inova Fairfax Hospital (S.C.C.), Falls Church, Virginia 22042; VA San Diego Healthcare System and University of California, San Diego (R.R.H., S.M.), San Diego, California 92093; Division of Endocrinology, Diabetes and Metabolism (A.E.K., F.B.S.), University of Tennessee-Memphis, Memphis, Tennessee; and Medstar Research Institute (R.E.R.), Hyattsville, Maryland 20782.
Thomas A BuchananTexas Diabetes Institute and University of Texas Health Science Center (D.T., N.M., R.A.D.), South Texas Veterans Health Care System, San Antonio, Texas 78229; Phoenix VA Health Care System (D.C.S., P.D.R.), Phoenix, Arizona 85012; College of Nursing & Health Innovation (D.C.S.), Arizona State University, Phoenix, Arizona 85281; SUNY Health Science Center at Brooklyn (M.A.B.), Brooklyn, New York 11203; Pennington Biomedical Research Center (G.A.B.), Louisiana State University, Baton Rouge, Louisiana 70803; University of Southern California Keck School of Medicine (T.A.B.), Los Angeles, California; Inova Fairfax Hospital (S.C.C.), Falls Church, Virginia 22042; VA San Diego Healthcare System and University of California, San Diego (R.R.H., S.M.), San Diego, California 92093; Division of Endocrinology, Diabetes and Metabolism (A.E.K., F.B.S.), University of Tennessee-Memphis, Memphis, Tennessee; and Medstar Research Institute (R.E.R.), Hyattsville, Maryland 20782.
Stephen C ClementTexas Diabetes Institute and University of Texas Health Science Center (D.T., N.M., R.A.D.), South Texas Veterans Health Care System, San Antonio, Texas 78229; Phoenix VA Health Care System (D.C.S., P.D.R.), Phoenix, Arizona 85012; College of Nursing & Health Innovation (D.C.S.), Arizona State University, Phoenix, Arizona 85281; SUNY Health Science Center at Brooklyn (M.A.B.), Brooklyn, New York 11203; Pennington Biomedical Research Center (G.A.B.), Louisiana State University, Baton Rouge, Louisiana 70803; University of Southern California Keck School of Medicine (T.A.B.), Los Angeles, California; Inova Fairfax Hospital (S.C.C.), Falls Church, Virginia 22042; VA San Diego Healthcare System and University of California, San Diego (R.R.H., S.M.), San Diego, California 92093; Division of Endocrinology, Diabetes and Metabolism (A.E.K., F.B.S.), University of Tennessee-Memphis, Memphis, Tennessee; and Medstar Research Institute (R.E.R.), Hyattsville, Maryland 20782.
Robert R HenryTexas Diabetes Institute and University of Texas Health Science Center (D.T., N.M., R.A.D.), South Texas Veterans Health Care System, San Antonio, Texas 78229; Phoenix VA Health Care System (D.C.S., P.D.R.), Phoenix, Arizona 85012; College of Nursing & Health Innovation (D.C.S.), Arizona State University, Phoenix, Arizona 85281; SUNY Health Science Center at Brooklyn (M.A.B.), Brooklyn, New York 11203; Pennington Biomedical Research Center (G.A.B.), Louisiana State University, Baton Rouge, Louisiana 70803; University of Southern California Keck School of Medicine (T.A.B.), Los Angeles, California; Inova Fairfax Hospital (S.C.C.), Falls Church, Virginia 22042; VA San Diego Healthcare System and University of California, San Diego (R.R.H., S.M.), San Diego, California 92093; Division of Endocrinology, Diabetes and Metabolism (A.E.K., F.B.S.), University of Tennessee-Memphis, Memphis, Tennessee; and Medstar Research Institute (R.E.R.), Hyattsville, Maryland 20782.
Abbas E KitabchiTexas Diabetes Institute and University of Texas Health Science Center (D.T., N.M., R.A.D.), South Texas Veterans Health Care System, San Antonio, Texas 78229; Phoenix VA Health Care System (D.C.S., P.D.R.), Phoenix, Arizona 85012; College of Nursing & Health Innovation (D.C.S.), Arizona State University, Phoenix, Arizona 85281; SUNY Health Science Center at Brooklyn (M.A.B.), Brooklyn, New York 11203; Pennington Biomedical Research Center (G.A.B.), Louisiana State University, Baton Rouge, Louisiana 70803; University of Southern California Keck School of Medicine (T.A.B.), Los Angeles, California; Inova Fairfax Hospital (S.C.C.), Falls Church, Virginia 22042; VA San Diego Healthcare System and University of California, San Diego (R.R.H., S.M.), San Diego, California 92093; Division of Endocrinology, Diabetes and Metabolism (A.E.K., F.B.S.), University of Tennessee-Memphis, Memphis, Tennessee; and Medstar Research Institute (R.E.R.), Hyattsville, Maryland 20782.
Sunder MudaliarTexas Diabetes Institute and University of Texas Health Science Center (D.T., N.M., R.A.D.), South Texas Veterans Health Care System, San Antonio, Texas 78229; Phoenix VA Health Care System (D.C.S., P.D.R.), Phoenix, Arizona 85012; College of Nursing & Health Innovation (D.C.S.), Arizona State University, Phoenix, Arizona 85281; SUNY Health Science Center at Brooklyn (M.A.B.), Brooklyn, New York 11203; Pennington Biomedical Research Center (G.A.B.), Louisiana State University, Baton Rouge, Louisiana 70803; University of Southern California Keck School of Medicine (T.A.B.), Los Angeles, California; Inova Fairfax Hospital (S.C.C.), Falls Church, Virginia 22042; VA San Diego Healthcare System and University of California, San Diego (R.R.H., S.M.), San Diego, California 92093; Division of Endocrinology, Diabetes and Metabolism (A.E.K., F.B.S.), University of Tennessee-Memphis, Memphis, Tennessee; and Medstar Research Institute (R.E.R.), Hyattsville, Maryland 20782.
Robert E RatnerTexas Diabetes Institute and University of Texas Health Science Center (D.T., N.M., R.A.D.), South Texas Veterans Health Care System, San Antonio, Texas 78229; Phoenix VA Health Care System (D.C.S., P.D.R.), Phoenix, Arizona 85012; College of Nursing & Health Innovation (D.C.S.), Arizona State University, Phoenix, Arizona 85281; SUNY Health Science Center at Brooklyn (M.A.B.), Brooklyn, New York 11203; Pennington Biomedical Research Center (G.A.B.), Louisiana State University, Baton Rouge, Louisiana 70803; University of Southern California Keck School of Medicine (T.A.B.), Los Angeles, California; Inova Fairfax Hospital (S.C.C.), Falls Church, Virginia 22042; VA San Diego Healthcare System and University of California, San Diego (R.R.H., S.M.), San Diego, California 92093; Division of Endocrinology, Diabetes and Metabolism (A.E.K., F.B.S.), University of Tennessee-Memphis, Memphis, Tennessee; and Medstar Research Institute (R.E.R.), Hyattsville, Maryland 20782.
Frankie B StentzTexas Diabetes Institute and University of Texas Health Science Center (D.T., N.M., R.A.D.), South Texas Veterans Health Care System, San Antonio, Texas 78229; Phoenix VA Health Care System (D.C.S., P.D.R.), Phoenix, Arizona 85012; College of Nursing & Health Innovation (D.C.S.), Arizona State University, Phoenix, Arizona 85281; SUNY Health Science Center at Brooklyn (M.A.B.), Brooklyn, New York 11203; Pennington Biomedical Research Center (G.A.B.), Louisiana State University, Baton Rouge, Louisiana 70803; University of Southern California Keck School of Medicine (T.A.B.), Los Angeles, California; Inova Fairfax Hospital (S.C.C.), Falls Church, Virginia 22042; VA San Diego Healthcare System and University of California, San Diego (R.R.H., S.M.), San Diego, California 92093; Division of Endocrinology, Diabetes and Metabolism (A.E.K., F.B.S.), University of Tennessee-Memphis, Memphis, Tennessee; and Medstar Research Institute (R.E.R.), Hyattsville, Maryland 20782.
Nicolas MusiTexas Diabetes Institute and University of Texas Health Science Center (D.T., N.M., R.A.D.), South Texas Veterans Health Care System, San Antonio, Texas 78229; Phoenix VA Health Care System (D.C.S., P.D.R.), Phoenix, Arizona 85012; College of Nursing & Health Innovation (D.C.S.), Arizona State University, Phoenix, Arizona 85281; SUNY Health Science Center at Brooklyn (M.A.B.), Brooklyn, New York 11203; Pennington Biomedical Research Center (G.A.B.), Louisiana State University, Baton Rouge, Louisiana 70803; University of Southern California Keck School of Medicine (T.A.B.), Los Angeles, California; Inova Fairfax Hospital (S.C.C.), Falls Church, Virginia 22042; VA San Diego Healthcare System and University of California, San Diego (R.R.H., S.M.), San Diego, California 92093; Division of Endocrinology, Diabetes and Metabolism (A.E.K., F.B.S.), University of Tennessee-Memphis, Memphis, Tennessee; and Medstar Research Institute (R.E.R.), Hyattsville, Maryland 20782.
Peter D ReavenTexas Diabetes Institute and University of Texas Health Science Center (D.T., N.M., R.A.D.), South Texas Veterans Health Care System, San Antonio, Texas 78229; Phoenix VA Health Care System (D.C.S., P.D.R.), Phoenix, Arizona 85012; College of Nursing & Health Innovation (D.C.S.), Arizona State University, Phoenix, Arizona 85281; SUNY Health Science Center at Brooklyn (M.A.B.), Brooklyn, New York 11203; Pennington Biomedical Research Center (G.A.B.), Louisiana State University, Baton Rouge, Louisiana 70803; University of Southern California Keck School of Medicine (T.A.B.), Los Angeles, California; Inova Fairfax Hospital (S.C.C.), Falls Church, Virginia 22042; VA San Diego Healthcare System and University of California, San Diego (R.R.H., S.M.), San Diego, California 92093; Division of Endocrinology, Diabetes and Metabolism (A.E.K., F.B.S.), University of Tennessee-Memphis, Memphis, Tennessee; and Medstar Research Institute (R.E.R.), Hyattsville, Maryland 20782.
Ralph A DeFronzoTexas Diabetes Institute and University of Texas Health Science Center (D.T., N.M., R.A.D.), South Texas Veterans Health Care System, San Antonio, Texas 78229; Phoenix VA Health Care System (D.C.S., P.D.R.), Phoenix, Arizona 85012; College of Nursing & Health Innovation (D.C.S.), Arizona State University, Phoenix, Arizona 85281; SUNY Health Science Center at Brooklyn (M.A.B.), Brooklyn, New York 11203; Pennington Biomedical Research Center (G.A.B.), Louisiana State University, Baton Rouge, Louisiana 70803; University of Southern California Keck School of Medicine (T.A.B.), Los Angeles, California; Inova Fairfax Hospital (S.C.C.), Falls Church, Virginia 22042; VA San Diego Healthcare System and University of California, San Diego (R.R.H., S.M.), San Diego, California 92093; Division of Endocrinology, Diabetes and Metabolism (A.E.K., F.B.S.), University of Tennessee-Memphis, Memphis, Tennessee; and Medstar Research Institute (R.E.R.), Hyattsville, Maryland 20782.
Phoenix VA Health Care System · USThe University of Texas Health Science Center at San Antonio · USUniversity of Tennessee Health Science Center · USVA San Diego Healthcare System · USInova Fairfax Hospital · USMedStar Health · USPennington Biomedical Research Center · USSUNY Downstate Health Sciences University · USTexas Diabetes Institute · USUniversity of Southern California · US
Funding
Southern California Clinical and Translational Science InstituteUL1TR000130 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2012 to 2015
$36.0MSan Antonio OAIC - Research Education Component (REC)P30AG044271 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Adam Salmon, Elena Volpi · 2015 to 2026
$14.1MRole of TLR4 on insulin resistance in humansR01DK080157 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI MUSI, NICOLAS · 2008 to 2017
$3.0MNCATS NIH HHS UL1 TR000130NIA NIH HHS P30 AG044271NIDDK NIH HHS R01 DK080157
Abstract
contextThiazolidinediones have proven efficacy in preventing diabetes in high-risk individuals. However, the effect of thiazolidinediones on glucose tolerance after cessation of therapy is unclear.
objectiveTo examine the effect of pioglitazone (PIO) on incidence of diabetes after discontinuing therapy in ACT NOW. Design, Settings and Patients: Two-hundred ninety-three subjects (placebo [PLAC], n = 138; PIO, n = 152) completed a median followup of 11.7 mo after study medication was stopped.
resultsDiabetes developed in 138 (12.3%) of PLAC vs 17 of 152 PIO patients (11.2%; P = not significant, PIO vs PLAC). However, the cumulative incidence of diabetes from start of study medication to end of washout period remained significantly lower in PIO vs PLAC (10.7 vs 22.3%; P < .005). After therapy was discontinued, 23.0% (35/152) of PIO-treated patients remained normal-glucose tolerant (NGT) vs 13.8% (19/138) of PLAC-treated patients (P = .04). Insulin secretion/insulin resistance index (I0-120/G0-120 × Matsuda index) was markedly lower in subjects with impaired glucose tolerance (IGT) who converted to diabetes during followup vs those who remained IGT or NGT. The decline in-cell function (insulin secretion/insulin resistance index) was similar in subjects with IGT who developed diabetes, irrespective of whether they were treated with PIO or PLAC.
conclusions1) The protective effect of PIO on incidence of diabetes attenuates after discontinuation of therapy, 2) cumulative incidence of diabetes in individuals exposed to PIO remained significantly (56%) lower than PLAC and a greater number of PIO-treated individuals maintained NGT after median followup of 11.4 mo, and 3) low insulin secretion/insulin resistance index is a strong predictor of future diabetes following PIO discontinuation.
Indexed as
Blood GlucoseDiabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsIncidenceInsulinInsulin ResistanceMaleMiddle AgedPioglitazoneSubstance Withdrawal SyndromeThiazolidinedionesBlood GlucoseHypoglycemic AgentsInsulinPioglitazoneThiazolidinediones
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.